This clinical study proposes to evaluate the combination of maraviroc with an integrase
strand transfer inhibitor (either raltegravir or dolutegravir) in antiretroviral-experienced
patients to document the efficacy, safety, and tolerability of this combination in order to
provide clinicians with a treatment regimen that minimizes the risk of metabolic
complications by avoidance of NRTI/NNRTIs and PIs. The development of an alternative ART
regimen which lessens the risk of metabolic complications could improve long-term adherence
and reduce the risk of certain co-morbidities associated with long-term ART use. If this new
combination is found to be as efficacious as the standard regimen with enhanced tolerability
and improved metabolic effects, there is great potential for altering the current practice of
HIV medicine.
Phase:
Phase 3
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore